Tanaka S, Takahashi T, Takayanagi H, Miyazaki T, Oda H, Nakamura K, Hirai H, Kurokawa T
Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Japan.
J Bone Miner Res. 1998 Nov;13(11):1714-20. doi: 10.1359/jbmr.1998.13.11.1714.
We have explored the use of adenovirus vector-mediated gene transfer to introduce foreign genes into osteoclasts, terminally differentiated cells responsible for bone resorption. A replication-deficient adenovirus vector that contains a reporter gene encoding beta-galactosidase efficiently infected human osteoclast-like cells (OCLs) derived from human giant cell tumors and mouse OCLs formed in vitro. We then constructed an adenovirus vector carrying human epidermal growth factor receptor (EGFR) cDNA (Ax1CAhEGFR) and introduced the EGFR gene into mouse OCLs. Clear induction of EGF receptor was detected in Ax1CAhEGFR-infected OCLs (EGFR-OCLs) by immunocytochemistry and immunoblotting, and EGF stimulation induced rapid tyrosine phosphorylation of several proteins including EGF receptor itself. Large vacuoles appeared in EGFR-OCLs in response to EGF treatment, and pit-forming activity by EGFR-OCLs was dose-dependently suppressed by recombinant human EGF. In addition, survival of EGFR-OCLs was prolonged by EGF. No expression of EGF receptor or effects of EGF were observed in noninfected OCLs or control vector-infected OCLs. These results suggest that adenoviral vectors are useful for modulating osteoclast function by introducing foreign genes into osteoclasts and that they will be a good means of gene therapy of metabolic bone diseases.
我们已经探索了利用腺病毒载体介导的基因转移将外源基因导入破骨细胞,破骨细胞是负责骨吸收的终末分化细胞。一种含有编码β-半乳糖苷酶报告基因的复制缺陷型腺病毒载体能够有效地感染源自人巨细胞瘤的人破骨样细胞(OCLs)以及体外形成的小鼠OCLs。然后我们构建了携带人表皮生长因子受体(EGFR)cDNA的腺病毒载体(Ax1CAhEGFR),并将EGFR基因导入小鼠OCLs。通过免疫细胞化学和免疫印迹在Ax1CAhEGFR感染的OCLs(EGFR-OCLs)中检测到EGF受体的明显诱导,并且EGF刺激诱导了包括EGF受体自身在内的几种蛋白质的快速酪氨酸磷酸化。响应于EGF处理,EGFR-OCLs中出现大液泡,并且重组人EGF剂量依赖性地抑制了EGFR-OCLs的蚀坑形成活性。此外,EGF延长了EGFR-OCLs的存活时间。在未感染的OCLs或对照载体感染的OCLs中未观察到EGF受体的表达或EGF的作用。这些结果表明腺病毒载体可用于通过将外源基因导入破骨细胞来调节破骨细胞功能,并且它们将是代谢性骨疾病基因治疗的良好手段。